SANEMUS AG

What is SANEMUS AG?

SANEMUS AG is a specialized investment fund that focuses on corporate and asset investments in the German healthcare market. Founded in 2006 in Munich, Germany by experienced professionals in the healthcare sector, they possess a profound expertise in equity investments, particularly within the private equity fund spectrum.

Their primary investment interest lies in life sciences, encompassing submarkets such as the pharmaceutical industry, biotechnology, medical technology, diagnostics, and e-health. They aim to turn promising startups in the life science sector into thriving businesses by offering complementary strategic and financial advisory services.

SANEMUS AG is dedicated to enhancing the value creation of life science companies through life-cycle and portfolio management as well as strategic partnering. Advising investors on life science investments, whether in individual projects or funds, the firm seeks to achieve optimal, individualized investment growth.

Additionally, SANEMUS AG provides strategic, financial, and merger & acquisition advisory to third parties. The company's track record and network within the industry support its position as a competent partner in the life science field. They engage in fostering the biotech sector by ensuring adequate venture capital funding, especially during the crucial seed phase of startups.

SANEMUS AG’s team consists of experienced advisors including Dr. Michael Thiel, who contributes insight into the German biotech-pharma scene and is involved in determining the eligibility of projects for government funding programs such as GO-Bio next.

Their commitment to the industry is further evident in their active discourse on financial trends and challenges in the biotech sector, through publications and participation in expert panels.